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Abstract 
 
There are many new pharmaceuticals being developed for the treatment of various diseases. One 
of the major issues these drugs face is the ability to enter a cell or the area of treatment. The 
current methods for drug delivery are often arduous to complete and do not make it to the 
diseased area because they are targeted by the immune system. In order to improve the ability for 
drugs to reach the desired area we propose the use of exosomes. Exosomes are subcellular 
vesicles that are responsible for the transport of biomaterials or signals within the cell and to 
other cells. The size of exosomes is small, around 30 nanometers is the average size, which 
minimizes the potential for immune targeting and also allows them to cross the blood brain 
barrier. In this project we look at the ability to tag, or add a protein, to the surface of an exosome. 
The fluorescent protein illustrates the location of the exosome within the cell and its potential to 
be tagged with other proteins to target various types of cells. Engineering exosomes has the 
potential to solve the current issues with drug delivery.    
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Chapter 1:  Introduction  
 
1.1 Background 
 
The treatment of cancer is limited to surgery, chemotherapy, and radiation. The first line of 
tumor removal is surgery but depending on the progression of the disease, sometimes surgery 
cannot be performed. Surgery alone does not ensure complete removal of cancerous cells, 
prompting the use of radiation and chemotherapy. These treatments can help patients achieve 
remission but it is common for cancer to recur. In 2014 there were nearly 14.5 million cancer 
diagnoses in the United States and it is expected to rise to almost 19 million by 2024 according 
to the National Cancer Institute. As cancer rates rise there needs to be alternative, more effective 
therapy than those currently in practice. The large number of cancer cases has translated to a 
large field of cancer research. Cellular and protein based therapies are popular potential 
therapies, however, we are looking to go deeper. Our work is focused on developing the base for 
a novel, nanoscale system with applications in cancer therapies. Specifically, we are looking to 
utilize the exosome vesicle for protein attachment. 
 
1.2 Review of the Field 
 
Exosomes have been increasingly studied due to their previously less known role within the cell 
and potentially useful structure. Exosomes are classified as extracellular vesicles; they are 
proteolipids with a bilayer, containing lipids, proteins, mRNAs, and microRNAs (Ref. 1). The 
contents of extracellular vesicles are not random; they maintain specific amounts of the 
aforementioned products. This is important to the study of extracellular vesicles, specifically 
exosomes, because their molecular mechanisms such as sorting and biogenesis can be 
understood in more detail. Intercellular and intracellular communication can be researched 
further. Exosomes are secreted by “fusion of late endosomes or multivesicular bodies with the 
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plasma membrane” (Ref. 1). As more components of extracellular vesicles are discovered and 
studied, the greater the chance for use as biomarkers or immunotherapies.  
Cell to cell communication is reliant on extracellular vesicles because they are able to travel to 
distant cells. Vesicles communicate with cells through transfer of proteins, lipids, and nucleic 
acids (Ref. 2). They are also able to signal various biological processes. These include antigen 
presentation and are therefore involved in immunological regulation, transfer transcription 
factors, oncogenes, and pathogens, in addition, they are able to transfer mRNAs and regulatory 
RNAs (Ref. 2). Exosomes have a large impact on the various processes conducted in and out of 
the cell, as well as the introduction of outside products or components, creating the potential for 
drug delivery, immunological stimulation, and disease biomarking. Exosomes are also present in 
the brain; they are implicated to be involved with synaptic neurotransmission (Ref. 2). Further, it 
is has been implicated that exosomes have a role in phenotypic modulation and tissue 
regeneration post injury. One of the most important implications of exosomes is in disease 
pathogenesis. One of the more understood exosome related pathologies is tumorigenesis, as 
exosomes can be involved in the coagulation, proliferation, and immune escape (Ref. 2). 
Improving the understanding of the role of exosomes in pathogenesis has the possibility of 
altering the exosomes involvement to prevent the disease from proliferating (Ref. 2-3). 
 
1.3 Literature Review 
 
Cancer research has forced scientists to rethink ideas and discover more intuitive ways of 
diagnosing and treating patients.  Even with current technology many of treatments are unable to 
accurately assess the potential cancers (Ref. 4).  However exosomes are new potential method 
for overcoming these issues.  Considering that cells naturally secrete exosomes, the ability to 
identify exosomes from different cell types became a field of interest.  Recent studies found that, 
with some degree of accuracy, identify between exosomes produced by lung tumors and 
exosomes produced by healthy cells (Ref. 4).  Current techniques do not necessarily possess a 
high enough level of accuracy for clinical use. However, expansion on this work could lead to 
improved diagnostic techniques.  The important barrier here is developing a more fundamental 
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understanding of exosomal surface which are the markers used by scientists to construct 
diagnostic tests (Ref. 4).  
Additionally, research is being conducted regarding the contents of exosomes, as a method to 
develop a greater understanding of their origin.  One group has discovered that oncogene 
amplifiers and certain DNA fragments linked with tumor growth have been isolated in some 
exosomes (Ref. 5).  This offers an alternative solution to our approach that focuses not on the 
external focus of exosomes but instead their cargo. While we have chosen to focus on surface 
proteins, potential of such cargo detection techniques should not be ignored. Our project hopes to 
open the door to more than diagnostic methods, ultimately the goal is new therapy 
development.    
In order to develop robust drug delivery, a broader understanding exosome function is necessary. 
Exosomes role in both the development of tumors and potential therapies stems a more broad 
knowledge of their role in the body (Ref. 6).  Specifically their role in the body’s immune 
response is an area of interest and as a result a display system must be established. To 
accomplish this display system we must turn our focus to membrane proteins and unlock 
mechanisms by which they can be manipulated.  
A recent surge in exosomal research serves to validate the work we are doing and while the 
methodological approach might change we feel that our system is justified to help us achieve our 
ultimate goals.   
 
1.4 Project Goal and Objectives 
 
This project is dedicated to modification and imaging of exosomes which have been modified 
and fluorescently tagged.  By developing a deeper understanding of the exosomal surface protein 
we can begin to explore these nanoparticles unique potential for targeted drug delivery or role as 
cell messengers.  
The first milestone is to develop the protocols necessary for creating and maintaining cell lines 
that express fluorescently tagged GFP.  Using previously established techniques we will be able 
to create and passage these cells for further study.   
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Once this has been established we will work extensively on the imaging of these cells.  This 
process will occur in two distinct phases.  The first will involve imaging with an optical 
microscope and the second will require the use of a confocal microscope.   
After extensive imaging has conducted we will move forward with further modifications of 
CD63.  We will use existing techniques and protein engineering to insert a new fluorescent tag 
into our exosomes and prove the robust nature of our established system.  
We expect to get a much better image of our modified exosomes by using the confocal lens 
which is capable of imaging specific layers within the cells.  Additionally, modifications with 
new fluorescent proteins should serve as additional proof that our system is in fact a robust 
method for the modification of surface exosomal proteins. 
 
1.5 Back-up Plan 
 
The main concern for our research is imaging the tetraspanin protein, CD63 .  This M-shaped 
protein appears to be the ideal scaffold for the attachment of targeting proteins. However, this 
unique shape could mean that alterations made to the protein could render the exosome unable to 
link to its target antigen.  Due to this fear, an alternative embedded protein on the surface of 
exosomes has been identified.  This alternative protein is a simple linear shape, which could 
allow for more versatility in terms of the antigen receptors we may target in the future.  CD63 is 
still our ideal target but the identification of a backup was necessary to guarantee the 
continuation of our research is complications were encountered. 
 
1.6 Significance 
 
Developing a novel system for drug delivery through the use of an exosome could have the 
potential to treat and/or cure cancer. In addition, it could be applied further to drug delivery in 
specific tissues or cells. The body naturally creates and secretes exosomes, so they are much less 
likely to be rejected or cause a reaction in the body if they are used for therapeutics. They are 
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accepted by cells and release their components within the cell, creating a potential drug delivery 
system. This could be used to heal specific parts of the body or the entire body. The drugs or 
therapies could also be highly patient specific, addressing the exact needs. The technology could 
be simplified to a level where expensive administration techniques could be diminished or 
eliminated for application to the developing world. Blood-borne pathogens and diseases specific 
to the developing world could be targeted and eliminated. Exosome based therapies have a great 
level of potential for curing disease and therapy development as they are readily accepted and 
exist in every part of the body.  
 
1.7 Team and Management 
 
Senior Design Team: 
Joseph Losacco 
Sophie McDevitt 
Zac Stickney 
Advisor: 
Dr. Biao (Bill) Lu 
 
1.8 Project Budget 
 
The most essential of those would be our cell line.  Without the HEK 293FT, the basic platform 
for our research, the entire project would not be possible.  The GFP and RFP genes are necessary 
due to their fluorescent nature.  These proteins allow for us to have visual confirmation of the 
effectiveness of our methods early on in our lab work.  The cell culture media is another essential 
purchase because it provides nutrients for the cells to grow and replicate.  Without the media the 
cells would die off.   
The School of Engineering Grant and Roelandts Grant ensured we had no difficulty obtaining the 
necessary materials required for this project.  
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1.9 Project Timeline 
 
Our team took the early opportunity to get into the lab to familiarize ourselves with the 
equipment and refine our protocols to guarantee effective practices.  Winter Break was again 
spent doing literature review.  Our team took this time to create a useful reference library that we 
would be able to emplace in our final thesis.  Winter quarter will be mainly spent in the lab 
executing our experiment.  Step one is to manipulate engineer the exosomes to contain GFP on 
the C terminus of CD63.  Once we have established a successful and effective method to execute 
step one we will begin to further engineer our exosomes. Extensive imaging will follow the 
success of this method.  Spring quarter will be spent finishing up our thesis and executing final 
tests to confirm our results.  Also during this time we will be passing off the project and cell lines 
to the next group that will further explore the increasing therapeutic possibilities this research 
can present.  
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Chapter: 2     Fluorescent Protein Insertion 
 
2.1 Introduction 
In order to glean a greater understanding of exosomes and their potential application to drug 
delivery applications, they must be modified and visualized. One of the most effective ways to 
visualize subcellular vesicles is attaching a fluorescent protein and viewing them using 
microscopy. Visualizing the cell after modification can depict the location of exosomes or an 
incorrect modification.  
Viewing specific cell structures, both in and outside of the cell requires luminescence; one of the 
best and most common ways to accomplish this is utilizing fluorescent proteins. Fluorescent 
proteins tend to be relatively large in size (~25 kD), especially in comparison to organic 
fluorophores which are in the ~1 kD range. The applications for fluorescent proteins are wide as 
they are functional in cellular and animal imaging (Ref 7). The fluorescent proteins, when 
attached to the proteins of interest, can allow observation of localization, movement, turnover, 
and time passed from synthesis. In addition, nucleic acids can be used for fluorescent protein 
attachment (Ref 8). Cells and tissue can be labeled with fluorescent protein in order to image the 
morphology, location, and movement of cells and tissue as well as the proliferation stages. The 
most useful application of fluorescent proteins to this project is their ability to tag vesicles and 
organelles. Fluorescent proteins attached or ‘tagged’ to vesicles through specific protein 
attachment, allow visualization of morphology, fusion/fission, and segregation due to cell 
division or other factors (Ref 8). In order to visualize the tagged structures, the sample must be 
stimulated with the corresponding frequency of the fluorescent protein in the sample.   
Exosomes are small vesicles, with a heterogenous size ranging from 30-100 nm and in order to 
better understand their behavior fluorescent proteins must be utilized (Ref 9). The insertion of a 
fluorescent protein into the exosome will either be successful or not. In addition, the insertion 
itself can provide greater information about the exosome activity.  
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In this experiment, Human Embryonic Kidney (HEK293) cells are utilized, as they are a highly 
stable mammalian cell line. This specific line has a greater passagability, it does not display 
mutagenesis in its morphology until the 100 passage time. This allows for easier maintenance 
and a lower cost for experimentation, as new cell lines were not required as frequently. In 
addition HEK293 cells have a high growth rate, allowing for quicker results. In addition, 
HEK293 cells have good transfectability, meaning potential for greater DNA insertion.  
 
Microscopy is the final and key piece of this project, as it will allow for the visualization of the 
insertion of the fluorescent proteins. The microscopes utilized were the Leica DMI3000 20x 
Inverted Microscope, 40x Zeiss Axioscope Fluorescence Microscope, and a 63x Confocal 
Microscope. The Leica microscope is the least powerful of the microscopes but it allows for 
quick visualization of cells within the lab. The Leica microscope allows for live cell visualization 
and fluorescence. The 40x Zeiss Axioscope Fluorescence Microscope is more powerful than the 
Leica and is utilized for its fluorescence. Finally, the Confocal Microscope is the most powerful 
imaging technology available for use. Its greatest advantages are its ‘z-slicing’ and high 
magnification properties. The ‘z-slicing’ feature allows the user to indicate a specific location on 
the z-axis in which to image the cells. This is highly advantageous to work with subcellular 
vesicles because they are much smaller in size.  
 
2.2 Key Constraints 
 
The key constraints of this experiment were the cell line used, the fluorescent proteins: GFP and 
RFP, and the microscopes used for imaging. 
 
2.3 Design Approach 
 
The four basic tenants of our experimental design are modifiability, human compatibility, ability 
to visualize, and maintenance of functionality. The design must be modifiable so that it can be 
altered if the original fluorescent proteins do not work initially or be applicable to different tags 
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and serve as a platform for different proteins or cells. Human compatibility is integral as the 
overarching goal for this research is targeted drug delivery in humans. There is limited research 
on the use of engineered exosome systems in mammalian cells but for the system to be 
successful it must work in humans. Using a mammalian cell line is the starting point for later use 
in humans. The system must allow for visualization in order to determine the location of the 
exosomes. Finally, the system must maintain its functionality. The platform or design should not 
breakdown over time, it should be able to maintain its integrity.  
 
In order to create this system, the CD63 tetraspanin is chosen as the target for modification. The 
CD63 protein crosses the exosome membrane four times, putting it in the tetraspanin class of 
proteins. This protein is one of the most abundant protein on the exosome surface and is 
oftentimes considered a key component of exosomes (Ref 10). In addition, CD63 has the 
potential for use as a scaffold.   
 
 
 
 
 
 	  
 
 
 
 
Figure 1 depicts the CD63 tetraspanin, a key part of this schematic is the C Terminus. For this 
design, GFP is inserted onto the C Terminus and nothing in the loops as indicated in Figure 2.  
 
Figure 1: Schematic of the CD63 Tetraspanin. 	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Figure 2: Schematic of the inserted GFP onto the C Terminus of CD63 
 
 
The GFP is attached to the C Terminus through the system indicated in Figure 3. The vector is 
constructed using constitutive cytomegalovirus (CMV) promoter, the CD63 virus, GFP, and a 
polyadenylation signal. EF1α with a puromycin resistance gene is incorporated.  
 
 
 
 
 
 
 
Figure 3: C Terminus vector for mammalian cell insertion. 
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This step allows for exosome fluorescence, in order to analyze their location a reference is 
necessary. Green fluorescence will also be inserted into the cytosol for imaging comparison.  
 
RFP is inserted into the nucleuses via transient transfection reagent. The cell line should express 
the GFP and RFP when imaged. These components should allow visualization of the location of 
exosomes relative the nucleus. The cells are imaged initially using the Leica DMI3000 20x 
microscope to ensure proper insertion of the fluorescence and analyze the location. After initial 
analysis, some cells are fixed onto glass coverslips in order for imaging by the40x Zeiss 
Axioscope Fluorescence Microscope and 63x Confocal Microscope. Fixation on glass coverslips 
is necessary for proper imaging. 
 
2.4 Supporting Analyses 
 
Exosome modification and imaging is a newer movement in current research. However, 
modification and imaging of other subcellular vesicles and bodies is not nearly as new. In order 
to image subcellular vesicles or bodies, plasmid based transfection is often utilized (Ref. 11). 
The liposome is a larger vesicle analogous to the structure of the exosome and more visualization 
has been conducted using exosomes. Fujii, et al. analyzed membrane protein visualization by 
inserting fluorescent proteins (Ref. 12). These authors were able to develop a system for surface 
display and then analyzed the varying fluorescence of the liposomes. The surface display system 
is applicable to other proteins in lipid-bilayer membranes (Ref. 13).  
 
However, the use of most plasmid-based transfection does not usually have a high rate of 
fluorescence. There are other ways to visualize these subcellular vesicles, one of these is the use 
of Cyto-Tracers (Ref. 11). Cyto-Tracer constructs encode fusion proteins; these proteins contain 
a targeting peptide and a fluorescent protein sequence. The targeting peptide should then guide 
the fluorescent protein to the correct location. The vector design presented in Figure 3, contains a 
Cyto-Tracer, indicated as CMV. Fong, et al. have shown success with Cyto-Tracers in 
mitochondria, peroxisomes, microtubules, and other intracellular structures. The work of these 
authors indicates that our experimental set up should yield proper fluorescence of the exosome. 
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2.5 Expected Results  
 
For the correct insertion of GFP and RFP, the exosomes should appear surrounding the nucleus. 
Microscopy should depict a red nucleus with green exosomes or endosome areas outside of the 
nucleus area. As exosomes are prepared for secretion, they remain in the endosomes, until 
secretion (Ref. 14). However, it is not expected that all nucleuses will fluoresce, as the insertion 
of RFP is the result of a transient transfection. Depending on the passage the nucleuses will 
fluoresce red but the percentage may vary.  
 
2.6 Backup Plan 
 
If this system does not work, the first step is to return to the traditional form of plasmid based 
fluorescent insertion for surface display. If reverting back to the traditional system, the 
fluorescent proteins will be reevaluated and replaced with different proteins or different forms of 
the initial fluorescent proteins to identify the problem.  
 
2.7 Full Protocol  
 
2.7.1 Cell Culture Basic Protocol:  
 
Protocol adapted from ThermoFisher 
 
Cell Culture Protocol 
Preparing Medium  
Prepare the complete D-MEM medium containing 10% FBS supplemented with 0.1 mM MEM 
Non-Essential Amino Acids, 1 mM sodium pyruvate and 2 mM Lglutamine 
1. Remove 1/10 of D-MEM and replace amount with 50 mL FBS. 
	   13	  
2. Also add:  
• L-Glutamine 
• Non-Essential Amino Acids (mix) 
• Sodium Pyruvate 
3. Sterilize the medium 
4. Store at 4°C 
 
Thawing 
1. Remove the vial of frozen cells from liquid nitrogen and thaw quickly in a       
37°C water bath. 
2. Decontaminate with ethanol solution and transfer to sterile tube with PBS. Then 
centrifuge and resuspend.  
3. Transfer cells to flask containing complete medium. 
4. Incubate flask.  
5. The next day aspirate off medium and replace with fresh medium.  
6. Incubate cells and check daily for 80-90% cell adherence.  
 
Freezing 
1. Freeze cells at 3 x 106 viable cells/mL density 
2. Prepare medium with 10% DMSO. Should be done immediately prior to use.  
3. Culture desired quantity to 70-90% adherence.  
4. Remove cells from tissue culture flask(s).  
5. Centrifuge the cells suspension, remove medium and resuspend cells in the pre-
determined volume of chilled freezing medium.  
6. Dispense aliquots of suspension into cryovials. 
7. Freeze cells in apparatus with temperature decrease of 1°C per minute.  
8. Transfer vials to liquid nitrogen storage.  
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2.7.2 Transfection into Mammalian Cells 
 
Protocol Adapted from ThermoFisher 
Mammalian Cell Transfection 
Check the confluency of your cells. They should be ~75-90% when transfecting  
Preparing your materials:  
1. Pre-heat cell media (dMEM+10%FBS)  
2. After checking cell confluency, wipe down the under surface of your cell plate 
with  
70% EtOH on a kimwipe and place in hood  
3. Turn on the aspirator and spray EtOH on the tubing that will be inside the hood  
4. Obtain proper pipettemans and pipette tips. Sterilize with EtOH  
5. Obtain three 1.5mL centrifuge tubes from your instructor 
6. Sterilize hands with EtOH before putting in hood.  
Transfections  
1. Label your 1.5mL tubes for the transfection reactions you calculated  
2. Add media to the tubes and then add the calculated amount of DNA. Mix 
thoroughly by pipetting  
3. Add the proper amount of Fugene6 DIRECTLY to the reaction without touching 
the sides of the tubes.  
4. Incubate for 10 minutes at RT inside the hood  
5. Aspirate off old media from the cells and replace with 2mL of new media. Add 
media to the side of the plate while tipping to prevent detachment of the cells  
6. Add the transfection reaction mixture dropwise to each well  
7. Tilt the plate back and forth to distribute the mixture evenly  
8. Put the plate in the 37C and check back at 24, 48, 72 hours to take fluorescent 
pictures 
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2.7.3 Cell Fixing  
Protocol Adapted from R&D Systems 
Cell Fixation on Glass Slips 
1. Culture cells by adding 500 µL of culture media containing approximately 5000 cells to 
the wells of a cell culture plate containing gelatin-coated coverslips. 
2. When cells have reached the desired density/age, remove the culture media from each 
well and wash twice with PBS. 
3. Add 300-400 µL of 2-4% Paraformaldehyde Fixative Solution to each well, and incubate 
for 20 minutes at room temperature. 
Note: Some cell types can be damaged by the change in surface tension that occurs when 
the culture medium is entirely removed and replaced with wash buffer. If this is the case, 
pre-fix the cells by adding 500 µL of 4% Formaldehyde Fixative Solution directly into the 
culture medium. After 2 minutes, replace the pre-fixation culture medium with 300-400 
µL of 2% Formaldehyde Fixative Solution and incubate, for 20 minutes at room 
temperature. 
4. Wash the wells twice with PBS and cover with 400 µL of wash buffer. The coverslips 
can be stored at 2-8 °C for up to 3 months or they may be stained immediately. 
Note: Fixation can result in hydrophobic cross-linking of tissue proteins. The time, 
temperature, pH, and fixative used will determine the degree of cross-linking. Once the 
fixation protocol has been optimized, the same procedure should be used consistently. 
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2.8 Results 
2.8.1 Brightfield Microscopy 
 
The Leica microscope is the least powerful of the microscopes utilized. Figure 4 depicts the GFP 
fluorescence in cells and those cells in a brightefield setting to illustrate the cell shape and 
location of exosomes. This pair of images indicates the exosomes are at the edge of the cell in 
the endosome space, indicating that the GFP vector targeted the exosomes. 
 
 
 
 
 
 
 
 
 
Figure 4: Exosomal GFP Tagged CD63. (A) Under Argon laser (B) Under white light.   	  	  
 
 
 
 
 
 
 
 
 
(A) (B) 
(A) (B) 
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Figure 5: Cytosolic GFP. (A) Cytosol under Argon laser (B) Cytosol under white light. 
 
In addition to the exosome fluorescence, the cytosol was targeted with GFP to depict the capacity 
of the GFP. The pair of images in Figure 5 are images of the same cell under the argon and 
brightfield conditions to indicate the shape.  
 
2.8.2 Zeiss Microscopy 
 
These images were obtained through the use of the Ziess Microscope. The images taken are of 
the same cell and surrounding area. The yellow arrow indicates the nucleus location in each 
image.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
(C) 
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Figure 6: Fluorescent Tagging. (A) Nuclear RFP insertion (B) Exosome GFP insertion (C) 
White light image.   
 
Zeiss microscopy allows for a greater magnification as compared to the Leica microscope. 
Figure 6 depicts the same area with RFP, GFP, and no fluorescence. The exosomes appear 
outside of the nucleus. These images further confirm the location of the exosomes and vector 
success. 
 
 
 
  
 
 
 
 
Figure 7: Nucleus RFP and Exosome GFP overlay. 
 
The images are then overlaid to more clearly show the location of the exosomes. The overlay 
depicts some overlap of the nucleus and exosomes but this is due to the three dimensional 
structure of the cell. The exosomes are not in the nucleus but they appear to based on imaging 
constraints. 
 
2.8.3 Confocal Microscopy  
Images taken using confocal microscopy. These images are at a significantly higher 
magnification than the prior images. The confocal microscope allowed for 0.5 micron cuts along 
the z-axis plane within the sample. The difficulty with the confocal imaging and Zeiss is the 
(C) 
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bleaching that occurred. Bleaching means the loss or minimization of fluorescence and it occurs 
when the cells are fixed on the coverslips and undergo imaging. The fixation of cells is necessary 
to image the sample but the bleaching minimizes the amount of time and areas available for 
imaging.  
 
 
 
 
 
 
 
 
 
 
(A)       (B) 
Figure 8: Confocal Images of RFP inserted nucleus and GFP inserted exosomes  
 
 
The images in Figure 8 depict the much higher microscopic power of the confocal microscope. 
Image (A) depicts the individual cell nucleus with RFP fluorescence overlaid with the GFP 
fluorescent exosomes. The exosomes appear below and over the nucleus however, cells and their 
components are three-dimensional and the location along the z-axis can cause the appearance of 
overlap.  
 
2.9 Discussion    
 
The insertion of fluorescence into exosomes was successful. The use of GFP and RFP in 
HEK293 proved to be a working combination when imaged with each microscope. The 
limitation we faced was using only fixed cells for imaging with the Zeiss and Confocal. If it was 
possible to image the live cells, we could have gleaned more information about the exosomes 
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and their movement within the cell and between cells as the Leica could not provide that level of 
detail.  
 
The Zeiss and Confocal microscope gave greater insight into the location of exosomes, 
particularly the confocal because of its ability to stack the images to form three-dimensional 
images in video form. We were able to use the software with the images we obtained to have a 
greater visualization of the nucleus and exosome locations. The Zeiss and Confocal microscopes 
are in the Biology Department, which created some difficulty for use of both devices as 
extensive scheduling and training was necessary for their use. We were very fortunate to access 
the machines at all but it would have been preferable to spend more time imaging the cells to 
analyze the insertion further.  
 
The exact location of the modification on or in the exosome cannot be known solely through 
imaging itself. Microscopes are not strong enough to view the surface proteins of exosomes. In 
order to evaluate the exact location of modification, other methods must be used such as 
antibody beads, which would link to the area of modification and provide greater validation of 
accuracy. If we had a greater amount of time with this project we could employ various forms of 
validation methods to identify the location of the modification.  
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Chapter 3:     Conclusions 
 
3.1 Summary and Conclusion 
 
Exosomal engineering has not been studied extensively but is quickly gaining more attention due 
to its potential in drug delivery, particularly its potential to target diseased cells such as cancer. 
The current options for drug therapeutics overwhelmingly face issues with delivery to the correct 
place with in the body and entrance into the cell. The pharmaceutical or drug that is being 
delivered may have a high potential to kill toxic cells or target a disease but due to the lack of 
deliverability the pharmaceutical is useless. Exosomes have the potential to overcome issues 
with deliverability as they are natural vesicles that travel throughout the body.  
 
To better gauge the potential for exosomes they must be modifiable. The exosome must be able 
to express or maintain a modification because modifications or engineering is required for their 
use in therapeutics, prior to carrying a pharmaceutical. In this project we used fluorescent 
proteins to gauge initial modifiability. The GFP insertion proved successful throughout the 
images we took on all microscopes. The areas outside of the nucleus fluoresced green which 
indicated that the correct vesicles were targeted. The exosomes tend to clump and because they 
are small in size the images could not depict each exosome individually but the groups. This 
project indicated that surface level expression modification does work.  
 
The next requirement of our design is that the exosomes must be human compatible. Exosomes 
are naturally forming and cell derived vesicles, by nature they should be human compatible. 
Much of the research conducted on exosomes is done using bacteria, not creating the standard of 
potential viability in humans. Mammalian cells are particularly different from bacterial cells and 
can be much more complex. For this reason, research conducted with exosomes should begin 
with human cell lines if the goal is to use it in humans later on. The research that we conducted 
used HEK293 cells or Human Embryonic Kidney cells throughout the project so that we focused 
solely on human exosomes within human cells.  
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In order to evaluate the success of modification within human cells, the modifications must be 
visualized. The best way for us to evaluate the modification and visualize it was to utilize 
fluorescent proteins. The success or failure of the modification would be visible using 
fluorescent microscopy. Each form of microscopy confirmed that the modification did occur and 
in the correct area. Incorrect modification would have produced fluorescence in the wrong areas 
or there would be an absence of fluorescence. Using three different types of microscopes with 
different magnifications allowed for further confirmation of modifiability. The Leica microscope 
served as the starting point for analyzing the cells. If there was no fluorescence with the Leica, 
we would have revisited the materials and protocol. The initial success prompted cell fixation for 
use of the Zeiss and Confocal microscopes. Both of these microscopes depicted the success of 
the modification as the nucleus and exosomal areas were in the proper areas.  
 
The exosomes must be able to maintain their modifications and maintain their functionality. 
Engineering exosomes should not result in a loss of capacity or ability to move between cells and 
the body as a whole. One of the first indicators of loss of function would be death and the 
exosomes would not fluoresce but with the scope of our project there is nothing direct we could 
do to determine their functionality after modification. The functionality of the exosome is an area 
that should be considered with follow on testing.  
 
This modification and imaging of the project proved promising, particularly with the use of high 
power microscopes even with the issue of bleaching. While cells were in living and fixed 
conditions, they depicted the modifications both of the nucleus and the exosomes.   
 
3.2 Project Future 
 
This initial project was successful which prompts the need for further investigation into the 
specific surface expression capacity of exosomes and their overarching ability for drug delivery. 
The future of this project should begin with analyzing the surface expression of exosomes. It 
should continue with a variation of modifications on CD63, applying these techniques to new 
membrane proteins.  
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The first step to carry on this project is to verify the exact location of the GFP on the cell. The 
project time did not allow us to verify the exact location, we were able to verify that the GFP was 
in the exosomes but not the exact location on the membrane. If the GFP is not located on the C 
Terminus, other techniques will need to be employed to rectify it. In addition, the CD63 
tetraspanin could be modified to better take on GFP or other proteins. The CD63 could be altered 
from the M shape it is currently to an N shape, potentially serving as an easier target for protein 
attachment. Many other types of proteins could be used, particularly those proteins specific to 
certain types of cells. Due to the size of exosomes, they are able to cross the blood brain barrier, 
a cell type to target would be neural cells. A protein that is key to the surface of neural cell 
attachment is NCAM or neural cell adhesion molecule which is a homophilic glycoprotein. 
NCAM is an example of molecules specific to certain cell types. Looking further into exosome 
targeting for specific cells could provide a greater amount of information on the potential of 
exosomes to carry pharmaceuticals to various parts of the body.  
 
Other follow on research could be conducted on the functionality of exosomes after 
modification. If they cannot maintain their biological integrity after modification of surface 
expression or attachment of tags, they lose their purpose. Drug delivery using exosomes relies on 
their functionality and capacity to deliver cargo within cells and ability to travel between cells. 
Further, functionality can be tested with an addition of a pharmaceutical within the exosome to 
deliver to specific cells. The exosome should be able to deliver the drug and maintain its 
functionality afterward. Toxicity of delivery can be tested and analyzed alongside this type of 
testing as well. Surface modifications and drug delivery can change potentially change the 
chemistry of exosomes and may lead to a change in toxicity of exosomes.  
 
3.3 Lessons Learned 
 
This project taught us a great deal about the importance of quality images from microscopy and 
scheduling. The Leica microscope proved to be a difficult microscope due to its limited 
magnification strength and the amount of other users. The Zeiss and Confocal microscopes were 
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far superior to the Leica but much harder to access because they are located in the Biology 
Department. In order to use the Zeiss and Confocal microscopes we were required to be trained 
on the microscopes but it was difficult to combine each person’s schedule. It was not until late 
into the timeline that we were able to use the microscopes. If we were able to improve our 
scheduling capacity we would have been able to enter in earlier and potentially take more images 
of the cells.  
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Chapter 4:     Engineering Standards 
 
4.1 Ethical Considerations 
 
The success of any project or research relies on the maintenance of ethical standards throughout 
the project and after. As representatives of Santa Clara University and as future members of the 
scientific and engineering communities, it is our duty to uphold these standards. The foundation 
of ethical conduct is honesty and integrity. In addition, Santa Clara University has its values that 
we must honor, the three C’s: conscience, competence, and compassion. These values, along 
with honesty and integrity, are the framework in which to conduct our research. Conscience is 
the first value, it requires us to identify and address the social issues or concerns affiliated with 
this type of project. The second value, competence, requires us to truly understand the subject 
matter of our research and how to conduct it. The third, compassion, is the basis of the project, as 
we are working to improve treatments for cancer, in order to improve the lives of patients. Each 
stage of the project and interactions among ourselves and with our advisors must adhere to these 
values.      
 
A comprehensive analysis of the ethics of our project requires us to consider the legal, 
environment, safety, manufacturability, and social concerns of our research.  
 
4.2 Legal Considerations 
 
The legal considerations of this project are minimal. Legal concerns encompass patent or 
intellectual property right infringement, additionally they should address the potential rights of 
this project. This system currently is entirely experimental with the data to be published within 
the scientific community. This project is academic with the goal to provide baseline research for 
the potential of exosomes to drug delivery systems.  
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This stage of the project would not apply to any intellectual property or patenting concerns as it 
not at the level for corporate application or interests. If this project continues further, particularly 
if the research reflected successful engineering of the outside of the exosome and a biomaterial 
or therapeutic insertion, this would be the point for patent application. The current state of this 
project is not applicable for this level of legal concern but it is a possibility in the future of this 
project.  
 
Additionally, business ties are not relevant to this project as there is no corporate involvement. 
The sole organization involved in this project is Santa Clara University, allowing us the freedom 
to research in an academic environment. The university may hold interest in publications but 
those provide benefits to the university, professor, and students but the university would not have 
an interest past that point.  
 
4.3 Environmental Considerations 	  
For any type of laboratory research the largest environmental concern is biohazardous waste 
being disposed of properly. The materials used have a minimal impact on the environment. The 
disposal methods the Bioengineering Department are in line with safety requirements mitigating 
the risk. The use and disposal of any biologics can pose a threat to environmental safety but this 
project did not utilize any toxins or pollutants, removing a direct environmental concern. 
However, being mindful of the correct disposal areas was necessary to prevent any negative 
effect on the environment. Additionally, we minimized our waste by reducing and reusing the 
materials and tools we used.  
 
4.4 Health and Safety Considerations 
 
Protecting the health and safety of those working on and around the project is paramount. Prior 
to entering the lab we completed the lab safety training courses conducted by Santa Clara 
University. These courses gave us the basic knowledge for proper lab conduct but we were given 
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further information from our advisor who walked us through the lab space. Throughout the 
project all lab protocol and conduct was honored, including protective clothing, gloves, and eye 
protection. The hood and ethanol was used in conjunction in order to prevent contamination or 
health concerns for the lab space.  
 
4.5 Manufacturability  
 
For any device or biologic, manufacturability must be considered to predict its capacity for 
scalable production. The exosome drug delivery system has the capacity to be manufactured in a 
lab setting. The desired function of the exosome system can be specifically engineered based on 
the drugs inserted and tagging on the surface for location targeting. The specific disease target 
system could be expanded by a pharmaceutical level company and then used for various patients. 
Such as any drug in the early stages, manufacturability and scaled production is far down the 
road but this system would allow for manufacturing at some stage in its development. A product 
or device with limited manufacturability forces the price to sky rocket or can majorly limit its 
accessibility.  
 
4.6 Social Considerations 	  
The success of a targeted drug delivery system would greatly improve the treatment of diseases 
in populations across the world. However, social considerations apply to this project and type of 
research. The first consideration is the materials used for research. The use of human embryonic 
kidney cells could be a point of consideration because the use of any type of embryonic cell is 
still a political and social issue in the United States. Each material or cell line used for research 
must be fully understood and be the most robust choice for research due to the issues 
surrounding cell research. If there are less contentious options with the same degree of 
robustness, those should be used. Once the research can project this system closer to clinical 
testing considerations should be made about the use of animal models. Minimizing the amount of 
animals used but maintaining proper data collection is a necessary consideration. Once in patient 
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testing, the system must not cause damage or harm to the patient and be used only with patients 
who can give informed consent.  Another major social consideration is the research cost and cost 
of the therapy upon introduction to the market. The development of disease treatment systems 
can cost an exorbitant amount, therefore the costs should be minimized and monetary funding 
used honestly. The next social monetary consideration is the cost of the system when introduced 
to market. Patients in need should be able to access it while compensating the parties involved in 
its development. The success of this system has the potential to treat various diseases, improving 
the quality of life and life expectancy for many people.   
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Appendix B- Protocol 
B.1 Cell Culture 
Preparing Medium  
Prepare the complete D-MEM medium containing 10% FBS supplemented with 0.1 mM MEM 
Non-Essential Amino Acids, 1 mM sodium pyruvate and 2 mM Lglutamine 
1. Remove 1/10 of D-MEM and replace amount with 50 mL FBS. 
2. Also add:  
• L-Glutamine 
• Non-Essential Amino Acids (mix) 
• Sodium Pyruvate 
3. Sterilize the medium 
4. Store at 4°C 
Thawing 
1. Remove the vial of frozen cells from liquid nitrogen and thaw quickly in a       
37°C water bath. 
2. Decontaminate with ethanol solution and transfer to sterile tube with PBS. Then 
centrifuge and resuspend.  
3. Transfer cells to flask containing complete medium. 
4. Incubate flask.  
5. The next day aspirate off medium and replace with fresh medium.  
6. Incubate cells and check daily for 80-90% cell adherence.  
Freezing 
1. Freeze cells at 3 x 106 viable cells/mL density 
2. Prepare medium with 10% DMSO. Should be done immediately prior to use.  
3. Culture desired quantity to 70-90% adherence.  
4. Remove cells from tissue culture flask(s).  
5. Centrifuge the cells suspension, remove medium and resuspend cells in the pre-
determined volume of chilled freezing medium.  
6. Dispense aliquots of suspension into cryovials. 
7. Freeze cells in apparatus with temperature decrease of 1°C per minute.  
8. Transfer vials to liquid nitrogen storage 
B.2 Transfection 
Check the confluency of your cells. They should be ~75-90% when transfecting  
Preparing your materials:  
1. Pre-heat cell media (dMEM+10%FBS)  
2. After checking cell confluency, wipe down the under surface of your cell plate 
with  
70% EtOH on a kimwipe and place in hood  
3. Turn on the aspirator and spray EtOH on the tubing that will be inside the hood  
4. Obtain proper pipettemans and pipette tips. Sterilize with EtOH  
5. Obtain three 1.5mL centrifuge tubes from your instructor 
6. Sterilize hands with EtOH before putting in hood.  
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Transfections  
1. Label your 1.5mL tubes for the transfection reactions you calculated  
2. Add media to the tubes and then add the calculated amount of DNA. Mix 
thoroughly by pipetting  
3. Add the proper amount of Fugene6 DIRECTLY to the reaction without touching 
the sides of the tubes.  
4. Incubate for 10 minutes at RT inside the hood  
5. Aspirate off old media from the cells and replace with 2mL of new media. Add 
media to the side of the plate while tipping to prevent detachment of the cells  
6. Add the transfection reaction mixture dropwise to each well  
7. Tilt the plate back and forth to distribute the mixture evenly  
8. Put the plate in the 37C and check back at 24, 48, 72 hours to take fluorescent 
pictures 
B.3 Cell Fixation 
1. Culture cells by adding 500 µL of culture media containing approximately 5000 cells to 
the wells of a cell culture plate containing gelatin-coated coverslips. 
2. When cells have reached the desired density/age, remove the culture media from each 
well and wash twice with PBS. 
3. Add 300-400 µL of 2-4% Formaldehyde Fixative Solution to each well, and incubate for 
20 minutes at room temperature. 
Note: Some cell types can be damaged by the change in surface tension that occurs when 
the culture medium is entirely removed and replaced with wash buffer. If this is the case, 
pre-fix the cells by adding 500 µL of 4% Formaldehyde Fixative Solution directly into the 
culture medium. After 2 minutes, replace the pre-fixation culture medium with 300-400 
µL of 2% Formaldehyde Fixative Solution and incubate, for 20 minutes at room 
temperature. 
4. Wash the wells twice with PBS and cover with 400 µL of wash buffer. The coverslips 
can be stored at 2-8 °C for up to 3 months or they may be stained immediately. 
Note: Fixation can result in hydrophobic cross-linking of tissue proteins. The time, 
temperature, pH, and fixative used will determine the degree of cross-linking. Once the 
fixation protocol has been optimized, the same procedure should be used consistently. 
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Appendix C- Project Management 
C.1 Budget 
Table B.1.1: Anticipated Budget 
Item Count Cost ($) 
Cell Line 1 400 
Vectors 2 400 
GFP RFP Genes 1 500 
Cell Culture Media 1 400 
Potential Necessary materials 1 350 
  
2,050 
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Appendix D- Senior Design Slides 
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